Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15171854 | 0.89 | GRM5 (0.46) | GRM5GRM1USP2SMN1; SMN2PDK4 | |
| SCHEMBL18293252 | 0.82 | PDK4 (0.48) | GRM5GRM1USP2SMN1; SMN2PDK4 | |
| SCHEMBL1122435 | 0.80 | ALDH1A1 (0.32) | GRM5GRM1SMN1; SMN2 | |
| SCHEMBL18068367 | 0.80 | PDK4 (0.46) | GRM5GRM1USP2SMN1; SMN2PDK4 | |
| SCHEMBL20459306 | 0.80 | PDK4 (0.49) | GRM5GRM1USP2SMN1; SMN2PDK4 | |
| SCHEMBL29233999 | 0.80 | PDK4 (0.46) | GRM5GRM1USP2SMN1; SMN2PDK4 | |
| SCHEMBL12999429 | 0.79 | GRM5 (0.53) | GRM5GRM1USP2SMN1; SMN2PDK4 | |
| SCHEMBL14028045 | 0.79 | PDK4 (0.50) | GRM5GRM1USP2SMN1; SMN2PDK4 | |
| SCHEMBL4083087 | 0.79 | PDK4 (0.48) | GRM5GRM1USP2SMN1; SMN2PDK4 | |
| SCHEMBL20841532 | 0.79 | GRM1 (0.46) | GRM5GRM1USP2SMN1; SMN2PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025066935-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | WO | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4384510-A1 | COMPOUNDS TARGETING MUTANT OF P53 | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| EP-1292576-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2003-03-19 | — | — | EP | disclosed |
| US-6509003-B2 | N-alkylpiperidine derivatives labeled with radioactive iodine; use in single photon emission computed tomography (SPECT) | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2003-01-21 | — | — | US | disclosed |
| EP-0989120-B1 | REAGENTS FOR ASSAYING CENTRAL LOCAL ACETYLCHOLINESTERASE ACTIVITY | DAIICHI PURE CHEMICALS CO LTD (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-6506773-B2 | For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration | DARWIN DISCOVERY LTD. (GB) | 2003-01-14 | — | — | US | disclosed |
| US-20020127180-A1 | Reagents for the determination of cerebral regional acetylcholinesterase activity | DAIICHI PURE CHEMICALS CO., LTD (JP) | 2002-09-12 | — | — | US | disclosed |
| US-20020022635-A1 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-02-21 | — | — | US | disclosed |
| WO-2001087844-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
| US-6306882-B1 | FLUOROALKYLPIPERIDINE ESTERS COGNITION ACTIVATORS AND ALZHEIMER'S | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-0989120-A1 | REAGENTS FOR ASSAYING CENTRAL LOCAL ACETYLCHOLINESTERASE ACTIVITY | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
| US-5837715-A | 3-fluoro-4-aminopiperidine derivatives as 5-HT receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | GRM5 2326/4885GRM1 1797/4885USP2 1336/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | GRM5 2326/4885GRM1 1797/4885USP2 1336/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | GRM5 3723/4885GRM1 3912/4885USP2 2162/4885 |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | GRM5 4744/4885GRM1 4808/4885USP2 4506/4885 |
| US-20020127180-A1 | Reagents for the determination of cerebral regional acetylcholinesterase activity | ACHE, BCHE, CHAT | GRM5 1096/4885GRM1 1007/4885USP2 2590/4885 |
| US-20020022635-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, HCAR3 | GRM5 36/4885GRM1 159/4885USP2 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.